Finch Therapeutics

About:

Finch Therapeutics is a microbiome development company that serve patients with serious unmet medical needs.

Website: http://finchtherapeutics.com/

Twitter/X: finch_tx

Top Investors: Avenir, Susquehanna International Group (SIG), MSD Capital, Willett Advisors LLC, MSD Partners

Description:

Finch Therapeutics is a mission-driven microbiome engineering company, is developing novel microbial therapies to serve patients with serious and unmet medical needs. The company uses machine learning algorithms to reverse engineer successful fecal transplantations and other clinical datasets, identifying the microbes that drive responses in patients. This human-centric discovery model leverages clinical data to focus on in-vitro and in-vivo efforts on cocktails of microbes that have already demonstrated safety and efficacy in humans. This enables early retirement of translational risk and avoids the challenges of extrapolating host-specific effects from animal models. Finch Therapeutics was founded in 2017 and is headquartered in Somerville, Massachusetts.

Total Funding Amount:

$189M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Somerville, Massachusetts, United States

Founded Date:

2017-01-01

Contact Email:

info(AT)finchtherapeutics.com

Founders:

Andrew Noh, Eric Alm, James Burgess, Mark Smith, Tom Borody, Zain Kassam

Number of Employees:

1-10

Last Funding Date:

2020-09-17

IPO Status:

Public

© 2024 MyAiNote.com